» Articles » PMID: 38006063

Longitudinal Analysis of Neuraminidase and Hemagglutinin Antibodies to Influenza A Viruses After Immunization with Seasonal Inactivated Influenza Vaccines

Overview
Date 2023 Nov 25
PMID 38006063
Authors
Affiliations
Soon will be listed here.
Abstract

Neuraminidase (NA)-based immunity could reduce the harmful impact of novel antigenic variants of influenza viruses. The detection of neuraminidase-inhibiting (NI) antibodies in parallel with anti-hemagglutinin (HA) antibodies may enhance research on the immunogenicity and duration of antibody responses to influenza vaccines. To assess anti-NA antibodies after vaccination with seasonal inactivated influenza vaccines, we used the enzyme-linked lectin assay, and anti-HA antibodies were detected in the hemagglutination inhibition assay. The dynamics of the anti-NA antibody response differed depending on the virus subtype: antibodies to A/H3N2 virus neuraminidase increased later than antibodies to A/H1N1pdm09 subtype neuraminidase and persisted longer. In contrast to HA antibodies, the fold increase in antibody titers to NA after vaccination poorly depended on the preexisting level. At the same time, NA antibody levels after vaccination directly correlated with titers before vaccination. A difference was found in response to NA antigen between split and subunit-adjuvanted vaccines and in NA functional activity in the vaccine formulations.

Citing Articles

Neuraminidase Antibody Response to Homologous and Drifted Influenza A Viruses After Immunization with Seasonal Influenza Vaccines.

Desheva Y, Sergeeva M, Kudar P, Rekstin A, Romanovskaya-Romanko E, Krivitskaya V Vaccines (Basel). 2025; 12(12.

PMID: 39771996 PMC: 11680112. DOI: 10.3390/vaccines12121334.


Occurrence of Circulating Antibodies against the Hemagglutinins of Influenza Viruses in the 2022/2023 Epidemic Season in Poland.

Kondratiuk K, Poznanska A, Szymanski K, Czajkowska E, Mankowski B, Brydak L Viruses. 2024; 16(7).

PMID: 39066267 PMC: 11281470. DOI: 10.3390/v16071105.


Anti-neuraminidase immunity in the combat against influenza.

Zhang X, Ross T Expert Rev Vaccines. 2024; 23(1):474-484.

PMID: 38632930 PMC: 11157429. DOI: 10.1080/14760584.2024.2343689.

References
1.
Desheva Y, Petkova N, Losev I, Guzhov D, Go A, Chao Y . Establishment of a Pseudovirus Platform for Neuraminidase Inhibiting Antibody Analysis. Int J Mol Sci. 2023; 24(3). PMC: 9916614. DOI: 10.3390/ijms24032376. View

2.
Halbherr S, Ludersdorfer T, Ricklin M, Locher S, Berger Rentsch M, Summerfield A . Biological and protective properties of immune sera directed to the influenza virus neuraminidase. J Virol. 2014; 89(3):1550-63. PMC: 4300740. DOI: 10.1128/JVI.02949-14. View

3.
Eichelberger M, Monto A . Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection. J Infect Dis. 2019; 219(Suppl_1):S75-S80. PMC: 7325326. DOI: 10.1093/infdis/jiz017. View

4.
Sultana I, Yang K, Getie-Kebtie M, Couzens L, Markoff L, Alterman M . Stability of neuraminidase in inactivated influenza vaccines. Vaccine. 2014; 32(19):2225-30. DOI: 10.1016/j.vaccine.2014.01.078. View

5.
Hendriks J, Holleman M, de Boer O, de Jong P, Luytjes W . An international technology platform for influenza vaccines. Vaccine. 2011; 29 Suppl 1:A8-11. DOI: 10.1016/j.vaccine.2011.04.124. View